Dawnrays Pharmaceutical (Holdings) Limited (02348.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 0.98

From 52W high−21.60%

Volume120000.00

Market capHKD 1.47B

P/E (TTM)5.5x

P/S (TTM)1.1x

Div yield4.90%

Key dataSep 18, 2026

Open

HKD 0.98

From 52W high

−21.60%

Volume

120000.00

Market cap

HKD 1.47B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

5.5x

RSI (14)

43.6

MomentumView details →

1D Return

+0.00%

YTD Return

−19.67%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

5.5x

EV/EBITDA

−0.9x

EV/Sales

−0.3x

P/S (TTM)

1.1x

P/B (TTM)

0.4x

ProfitabilityView details →

Gross Margin

47.81%

Net Margin

20.29%

EBITDA Margin

30.75%

ROE (TTM)

6.73%

ROA (TTM)

5.79%

Asset Turnover

0.28x

GrowthView details →

Revenue YoY

+2.29%

EPS YoY

+30.12%

FCF YoY

−28.58%

Revenue CAGR 3Y

−1.24%

EPS CAGR 3Y

−16.45%

EBITDA YoY

+54.61%

MomentumView details →

1D Return

+0.00%

YTD Return

−19.67%

1Y Return

−19.01%

RSI (14)

43.6

vs 50D SMA

−1.91%

vs 200D SMA

−11.39%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

5.38x

Quick Ratio

4.88x

Div Yield

4.90%

Div Rate

HKD 0.05

Div Growth 1Y

+18.75%

EarningsView details →

EPS (Actual)

HKD 0.09

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

2.25B

Net Income (TTM)

407.51M

Op. CF (TTM)

627.68M

Next earningsMar 19, 2027 →

Latest newsMore news →

Dongrui Pharmaceutical declared an interim dividend of HKD 0.015 per share for the six months ended June 2026, unchanged from the prior year.23d ago

Dongrui Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of RMB 546 million, down 13.4% year-on-year, and net profit of RMB 123 million, up 18% year-on-year.23d ago

Similar companies

Golden Throat Holdings Group Company Limited06896.HK Phibro Animal Health CorporationPAHC JBM (Healthcare) Limited02161.HK Jilin Province Huinan Changlong Bio-pharmacy Company Limited08049.HK Essex Bio-Technology Limited01061.HK ANI Pharmaceuticals, Inc.ANIP Find similar companies →

Latest newsMore news →

Dongrui Pharmaceutical declared an interim dividend of HKD 0.015 per share for the six months ended June 2026, unchanged from the prior year.23d ago Dongrui Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of RMB 546 million, down 13.4% year-on-year, and net profit of RMB 123 million, up 18% year-on-year.23d ago